Is the GSTM1 null polymorphism a risk factor in Primary Open Angle Glaucoma? by Rocha, Auta Viviane et al.
Is the GSTM1 null polymorphism a risk factor in Primary Open
Angle Glaucoma?
Auta Viviane Rocha,1 Teddy Talbot,1 Thiago Magalhães da Silva,1 Maria Clarinda Almeida,1
Carlos Alberto Menezes,1 Giuliano Di Pietro,2 Fabrício Rios-Santos1
1Universidade Estadual de Santa Cruz, Departamento de Ciências da Saúde, Laboratório de Farmacogenômica e Epidemiologia
Molecular (LAFEM), Ilhéus, Bahia, Brazil; 2Universidade Federal de Sergipe - Campus de Lagarto, Laboratório de Genética, São
Cristovão, Sergipe, Brazil
Purpose: To investigate the association of glutathione S-transferase (GST) GSTM1, GSTT1, and GSTP1 genes with the
risk of primary open angle glaucoma (POAG) and clinical features of the disease.
Methods: We conducted a case-control study that included 87 Brazilian patients with POAG and 85 healthy controls
matched for age, ethnicity, and sex, whose blood samples were genotyped for polymorphisms in GST genes using
polymerase chain reaction (PCR) based methods.
Results: The GSTM1 null polymorphism was significantly more common in the POAG than in the controls group (OR:
2.1, 95% CI: 1.13–3.9; p=0.018). The combined GSTM1 null/GSTT1+ genotype and GSTM1 null/GSTP1 Ile/Val or Val/
Val was more prevalent in POAG patients, being a risk factor for POAG (OR: 2.4, 95% CI: 1.16–4.9; p=0.016 and OR:
2.7, 95% CI: 1.07–6.74; p=0.033, respectively). The GSTM1 null/GSTT1+ genotype were associated with higher levels
of IOP of both eyes and with more severe defect of the right eye optic nerve. The GSTM1 null/GSTP1 Ile/Val or Val/Val
genotypes were associated with higher levels of IOP and more advanced defect of the right eye optic nerve and visual
field.
Conclusions: We demonstrate that GSTM1 null polymorphism is associated with POAG in the Brazilian population.
Glaucoma  is  a  progressive  neuropathy  which  has  a
characteristic pattern of optic nerve and visual field damage.
Primary open angle glaucoma (POAG) is the most common
form of glaucoma affecting 2% of the world’s population over
40  year’s  old  [1].  It  is  considered  the  second  cause  of
irreversible blindness worldwide. Quigley et al. [2] estimate
that 79.6 million people will be affected with glaucoma by
2020.
Although the pathophysiology is poorly understood, it is
believed that environmental and genetic factors may play an
important role in POAG. The increase of intra ocular pressure
(IOP) is known to be one of the major risk factors for the
disease. POAG exhibits a heritable susceptibility consistent
with a complex trait inheritance and only three genes have
been implicated in the pathogenesis of the disease, myocilin
(MYOC)  [3],  optineurin  (OPTN)  [3],  and  WD  repeat-
containing  protein  36  (WDR36)  [3].  Mutations  in  MYOC
account for 1%–4% of POAG depending on the population
studied [3]. Other studies suggest that oxidative stress may be
involved  in  the  pathophysiology  of  POAG  [4].  Chronic
oxidative  stress  may  contribute  to  increase  of  intraocular
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pressure by increased resistance of aqueous humor outflow
through trabecular meshwork (TM).
Glutathione  S-transferases  (GST)  are  polymorphic
enzymes that catalyze the neutralization of free radicals by
their  conjugation  with  glutathione  and  thus  render  the
products  more  water-soluble  [5].  Several  studies  have
demonstrated that GST genetic polymorphisms are associated
with  a  higher  risk  of  developing  POAG  in  different
populations [6,7]. However, these results were not confirmed
in other studies [8]. Thus, the aim of the present study was to
characterize  the  southern  Bahia,  Brazil  population  for
GSTM1, GSTT1, and GSTP1 polymorphisms and determine
the  relative  risk  of  POAG  associated  with  these
polymorphisms.
METHODS
Patients and controls: Eighty seven patients with POAG (27
men and 60 women; mean age 63.5±11.02) were recruited
from out-patient clinic and a group of 85 healthy controls (29
men and 56 women; mean age 61.8±11.23) originating from
public awareness programs on glaucoma donors and blood
banks were selected for the study. All individuals live in the
south of Bahia State, Brazil. Information concerning dietary
habits,  history  of  disease  and  lifestyle  (including  tobacco
smoking) was obtained from a socioeconomic questionnaire
administered to both groups. All volunteers signed a consent
form  approved  by  the  local  ethics  committee  of  the
Universidade Estadual de Santa Cruz (UESC).
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1679Clinical  evaluation:  All  patients  underwent  complete
ophthalmologic  evaluation  that  included  medical  history,
best-corrected  visual  acuity,  slit-lamp  biomicroscopy  with
and  without  dilation,  applanation  tonometry,  dilated
fundoscopy, ophthalmoscopy of the optic disk with a 78-
diopter  lens,  gonioscopy,  and  computerized  visual  fields.
Humphrey automated perimeter strategy C-24–2 visual field
was  done  for  glaucoma  patients  and  frequency  doubling
perimeter (FDT®) visual field for the controls. The inclusion
criteria for the case group were initial IOP (before treatment)
above 21 mmHg, defect suggestive of glaucoma on the optic
nerve  (ON)  and  visual  field  (VF).  Cup/Disc  ratio  was
measured according to Anderson's [9] criteria and optic nerve
defect was qualitatively analyzed and further defined using
standard  ranking  as  mild,  moderate  or  advanced  damage
according to the severity of the disease (Table 1). To evaluate
visual field damage, VF map was analyzed and VF score was
assigned according to the Brusini Glaucoma Staging System
[10].  Patients  with  history  of  surgery,  uveitis,  trauma  or
secondary glaucoma were excluded. The inclusion criteria for
the control group were IOP below 21 mmHg, the anterior
chamber angle open, optic nerve and visual fields without
abnormalities  suggestive  of  glaucoma.  Patients  with
malignant disease or autoimmune disease were excluded.
Sample  collection  and  DNA  analysis:  Ten  milliliters  of
peripheral blood was collected in EDTA vacutainer tubes
from all participating individuals after obtaining their written
consent. Genomic DNA extraction was performed from whole
blood using the FlexiGene DNA Kit (Qiagen, Boston, MA).
GSTM1, GSTT1, and GSTP1 polymorphism analyses were
performed  by  PCR  [11].  Briefly,  for  GSTM1  and  GSTT1
genotyping  50-500  ng  of  DNA  was  amplified  in  a  50-µl
multiplex reaction mixture containing 20 pmol of each of the
following GSTM1 primers (G1 - 5'-GAA CTC CCT GAA
AAG CTA AAG C-3' and G2 - 5'-GTT GGG CTC AAA TAT
ACG GTG G-3'), and of the following GSTT1 primers (T1 -
5'-TTC CTT ACT GGT CCT CAC ATC TC-3' and T2 - 5'-
TCA CCG GAT CAT GGC CAG CA-3'). As an internal
control, a fragment of the human b-globin gene was also
amplified (GH20 5'-GAA GAG CCA AGG ACA GGT AC-3'
and PC04 5'-CAA CTT CAT CCA CGT TCA CC-3') in a
medium consisting of 1.5 mM MgCl2, 200 µmol dNTPs, 5 µl
10× PCR buffer (10× 500 mM KCl, 100 mM Tris-HCl, pH
9.0), and 2 U TaqDNA polymerase (Promega, Madison, WI).
The PCR protocol included an initial melting temperature of
94 ºC (5 min) followed by 35 cycles of amplification (2 min
at 94 ºC, 1 min at 59 ºC, and extension for 1 min at 72 ºC). A
final 10-min extension step (72 ºC) terminated the process.
The final PCR product from co-amplification of GSTM1 (215
TABLE 1. CLASSIFICATION OF DEFECTS OF THE OPTIC NERVE DAMAGE.
Defect Type Description
0 Normal Without lesion
1 Initial defect Focal deficiency in 1 or more pole that do not reach up to the papillary edge
2 Small defect Focal deficiency in 1 pole that reach to the papillary edge
3 Middle Defect Focal deficiency in 1 or more pole that reach papillary edge (Notch)
4 Middle severe defect Focal deficiency in 1 or more pole that reach the papillary edge (Notch) plus hemorrhage or β zone
5 Severe defect Cup/Disc ratio above 09/09
6 Null Cup/Disc ratio total (10/10)
TABLE 2. DEMOGRAPHIC AND OPHTHALMOLOGIC DATA OF THE INDIVIDUALS STUDIED.
Variables Glaucoma group n=87 Control group n=85 p value*
Gender
Male 27 (31%) 29 (34..1%) 0.666
Female 60 (69%) 56 (65..9%)
Age (mean) 63..46 (±11.02) 61.67 (±11.23) 0.323
Ethnicity
White
1 17 (19.5%) 20 (23.5%) 0.609
Not White 70 (80.5%) 65 (76.5%)
IOP RE 26.73±3.38 14.28±2.18 p<0.001
IOP LE 26.19±3.93 13.95±1.99 p<0.001
C/D RE 0.8 (0.4–10) 0.3 (0.2–0.4) p<0.001
C/D LE 0.7 (0.4–10) 0.3 (0.2–0.4) p<0.001
        1According to each individual self-declared ethnicity (IBGE); IOP=intra ocular pressure in mmHg; RE: right eye; LE: left eye;
       C/D: cup disc/ratio. *Student t-test.
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1680bp)  and  GSTT1  (480  bp)  was  visualized  on  an  ethidium
bromide-stained  2.0%  agarose  gel.  The  subjects  were
classified as either positive (when at least one copy of the gene
was  present)  or  null  genotypes.  To  genotype  the  GSTP1
BsmaI polymorphism the PCR-RFLP method was applied as
follows: 50-500 ng of DNA was amplified in a total reaction
volume of 25 µl containing 20 mM Tris- HCl, 50 mM KCl,
1.5 mM MgCl2, 2 mM of each deoxynucleotide triphosphate,
100 ng/ µl of each primer (P105F 5'-ACC CCA GGG CTC
TAT GGG AA-3' and P105R 5'-TGA GGG CAC AAG AAG
CCC CT-3'), and 1.25 U AmpliTaq DNA polymerase. PCR
was carried out in an Eppendorf Gradient Thermocycler, with
5 min of pretreatment at 95 ºC, 30 cycles of 30 s at 57 ºC, 30
s at 72 ºC, and 30 s at 94 ºC, followed by 5 min at 72 ºC. After
amplification, PCR products (20 µl) were cleaved by 5 U
BsmaI  enzyme  at  55  ºC  for  2  h  and  then  subjected  to
electrophoresis on 3.5% agarose gel at 40 V for 2 h and
visualized using ethidium bromide. The primers P105F and
P105R  generated  an  amplified  fragment  of  176  bp
corresponding to the wild genotype (Ile/Ile). After cleavage
with  the  restriction  enzyme  BsmaI,  individuals  with  the
variant allele (Ile/Val) will show three bands of 176 (Ile), 91,
and 85 (Val) bp, respectively. The mutant homozygote (Val/
Val) has both alleles cleaved, showing two bands (81 and 91
bp).
Statistical analysis: Age of patients and control group was
compared using the Student t-test. χ2 test was used to assess
differences  in  allelic  and  genotype  frequencies  between
TABLE 3. RISK OF POAG BETWEEN GST GENOTYPES.
Genotype Cases n (%) Control n (%) OR (IC 95) p value*
GSTM1
GSTM1+ 44 (50.6) 58 (68.2) Ref. ־
GSTM1- 43 (49.4) 27 (31.8) 2.1 (1.13–3.9) 0.018
GSTT1
GSTT1+ 72 (82.8) 61 (71.8) Ref. ־
GSTT1- 15 (17.2) 24 (28.2) 0.53 (0.25–1.01) 0.085
GSTP1
Ile/Ile 44 (50.6) 45 (52.9) Ref. ־
Ile/Val 35 (40.2) 34 (40) 1.05 (0.56–2.0) 0.873
Val/Val 08 (09.2) 06 (07.1) 1.36 (0.44–4.25) 0.592
Ile/Val or Val/
Val
43 (49.4) 40 (47.1) 1.01 (0.6–2.0) 0.756
Ile 123 (71.0) 124 (73.0) Ref. ־
Val 51 (39.0) 46 (27.0) 1.12 (0.7–1.8) 0.643
Reference groups: GSTM1+ (non-deleted), GSTT1+ (non-deleted) and GSTP1 wild-type allele. *χ2 test.
TABLE 4. DISTRIBUTION OF GST GENOTYPES COMBINED BETWEEN CASES AND CONTROLS.
Genotype combinations Groups    
  Cases n (%) Controls n (%) OR (IC 95) p value*
GSTM1/GSTT1
M1+/T1+ 36 (41.4) 43 (50.6) Ref. ־
M1+/T1- 8 (9.2) 15 (17.6) 0.64 (0.24–1.67) 0.358
M1-/T1+ 36 (41.4) 18 (21.2) 2.4 (1.16–4.9) 0.016
M1-/T1- 7 (8) 9 (10.6) 0.93 (0.31–2.74) 0.894
GSTM1/GSTP1
M1+/Ile/Ile 24 (27.6) 28 (32.9) Ref. ־
M1+/ Ile/Val or Val/Val 20 (23.0) 30 (35.3) 0.78 (0.35–1.7) 0.53
M1-/ Ile/Val or Val/Val 23 (26.4) 10 (11.8) 2.7 (1.07–6.74) 0.033
M1-/Ile/Ile 20 (23.0) 17 (20) 1.37 (0.6–3.2) 0.463
GSTT1/GSTP1
T1+/Ile/Ile 35 (40.2) 34 (40.0) Ref. ־
T1+/ Ile/Val or Val/Val 37 (42.5) 27 (31.8) 1.33 (0.67–2.64) 0.412
T1-/ Ile/Val or Val/Val 6 (6.9) 13 (15.3) 0.45 (0.15–1.3) 0.138
T1-/Ile/Ile 9 (10.3) 11 (12.9) 0.8 (0.29–2.16) 0.652
                Reference groups: GSTM1+ (non-deleted), GSTT1+ (non-deleted) and GSTP1 wild-type allele. *χ2 test.
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1681groups. Odds ratio (OR) and confidence interval 95% (CI)
were  used  to  analyze  the  risk  of  POAG  associated  with
GSTM1,  GSTP1,  and  GSTT1  genotypes,  alone  or  in
combination. A multivariate logistic regression model was
applied  to  assess  the  risk  of  POAG  attributed  to
polymorphisms  of  GSTs  after  adjusting  for  gender,  age,
ethnicity and tobacco smoking. The reference group consisted
of individuals with three putative low-risk genotypes, i.e., the
presence of GSTM1 (non-deleted), GSTT1 (non-deleted), and
GSTP1  (homozygous  Ile-104)  functional  alleles.  ANOVA
(ANOVA)  was  used  to  assess  the  association  of  GST’s
genotype combinations with clinical parameters in the cohort
of  POAG  patients.  Kolmogorov–Smirnov  testing  was
performed on all data before analysis to determine if data was
normally  distributed.  Non-normally  distributed  data  was
analyzed  using  ANOVA  on  ranks  with  the  Tukey  test
employed for post hoc analysis. Mann–Whitney U test was
used to assess differences in clinical variables according to
GSTs genotypes. A Hardy–Weinberg equilibrium test was
also performed using χ2 tests. All tests were performed with
Statistical Package for the Social Sciences (SPSS-10, Inc.,
Chicago, IL).
RESULTS
The individuals enrolled for the study were matched for age,
sex, and ethnicity to obtain two homogeneous groups. The
glaucoma group consisted of 87 individuals (27 males and 60
females with the mean age of 63.5±11.02 years old). The
control group consisted of 85 individuals (29 males and 56
females with the mean age of 61.8±11.23 years old). There
was no statistically significant difference (p>0.05) regarding
gender and age between groups. On the other hand, cup/disc
ratio and IOP levels were almost two folds higher in the POAG
group when compared with the control group (0.8±0.1 and
0.3±0.1; p<0.001, respectively, Table 2).
The GSTM1 null genotype frequency was significantly
higher in POAG patients (49.4%) than in controls (31.8%).
The GSTM1 null genotype had an increased risk of developing
POAG (OR=2.01; 95% CI: 1.13–3.9; p=0.018). The GSTT1
null genotype was more frequent in the control group (28.2%)
than in the case group (17.2%). However, such difference was
TABLE 5. MEAN VALUES OF CLINICAL PARAMETERS EVALUATED FOR THE CASE GROUP ACCORDING TO THE GSTM1
GENOTYPES.
Variables Genotype n Mean SD p value*
IOPRb GSTM1- 34 24.44 5.58 0.009
  GSTM1+ 37 21 5.06  
IOPLb GSTM1- 34 23.65 6.24 0.035
  GSTM1+ 37 20.73 6.26  
ONR: DEF GSTM1- 39 2.54 2.11 0.006
  GSTM1+ 39 1.33 1.64  
ONL: DEF GSTM1- 39 2.21 2.1 0.186
  GSTM1+ 39 1.56 1.9  
VFMDR GSTM1- 37 −8.73 8.0 0.239
  GSTM1+ 33 −6.04 6.0  
VFPSDR GSTM1- 37 5.48 3.76 0.760
  GSTM1+ 33 5.61 3.09  
VFDEFR GSTM1- 38 3.11 2.31 0.033
  GSTM1+ 33 1.94 1.73  
VFMDL GSTM1- 37 −8.67 8.8 0.181
  GSTM1+ 31 −5.47 5.6  
VFPSDL GSTM1- 37 4.80 2.92 0.486
  GSTM1+ 31 5.46 2.95  
VFDEFL GSTM1- 38 2.79 2.27 0.279
  GSTM1+ 31 2.1 1.87  
        *Mann–Whitney test. IOPRb: Intra ocular pressure of right eye before treatment; IOPLb: Intra ocular pressure of left eye before
         treatment; ONR:DEF: right eye optic nerve defect; OotherL:DEF: left eye optic nerve defect; VFMDR: visual field mean
         deviation right eye; VFPSDR: visual field pattern standard deviation right eye; VFDEFR: visual field defect of right eye;
         VFMDL: visual field mean deviation of left eye; VFPSDL: visual field pattern standard deviation left eye; VFDEFL: visual
         field defect of left eye.
Molecular Vision 2011; 17:1679-1686 <http://www.molvis.org/molvis/v17/a186> © 2011 Molecular Vision
1682not statistically significant (OR: 0.53; 95% CI: 0.25–1.01;
p=0.085).  The  GSTP1  genotype  frequency  did  not  differ
between the two groups (Table 3).
The association between GSTM1 and POAG remained
statistically  significant  when  adjusted  for  gender,  age,
ethnicity,  tobacco  smoking  and  GSTs  genotypes  by
multivariate logistic regression model (OR=2.22; 95% CI:
1.14–4.31; p=0.018; data not shown).
Table 4 shows the frequency of combined genotypes. The
GSTM1  null/GSTT1+  was  significantly  higher  in  POAG
patients  than  in  controls  (OR=2.4;  95%  IC:  1.16–4.9;
p=0.016) and the association of genotypes GSMT1 null and
GSTP1 Ile/Val or Val/Val was also significant (OR=2.7; 95%
CI: 1.07–6.74; p=0.033). The difference in frequency of the
GSTM  null/GSTT  null  genotype  was  not  significant
(OR=0.93; 95% CI: 0.31–2.74; p=0.894).
Table 5 shows the clinical features associated with the
GSTM1  genotype  in  the  POAG  group  by  applying  the
nonparametric Mann–Whitney test. The results show that the
GSTM1  null  genotypes  were  associated  with  higher  IOP
values in right and left eyes (p=0.009 and 0.035, respectively).
Other  results  show  that  the  GSTM1  null  genotypes  are
associated with severe optic nerve damage (grade 4; p=0.006).
The differences were not statistically significant (data not
shown) for the GSTP1 and GSTT1 genotypes.
The gene-gene interaction between GSTM1 and GSTT1
genotypes was tested using ANOVA and shows a statistically
significant difference for the variable initial IOP of the right
eye  (F=4,43;  p=0.007;  Figure  1)  and  left  eye  (F=4,32;
p=0.008); and optic nerve damage (F=3,32; p=0.024). The
interaction of GSTM1 and GSTP1 genotypes was statistically
significant  for  initial  IOP  (F=3,62;  p=0.018),  visual  field
defect  (3,78;  p=0.014)  and  optic  nerve  damage  (F=5,6;
p=0.002; Figure 2).
DISCUSSION
Although  POAG  physiopathology  still  remains  partially
unclear,  there  are  evidences  that  reactive  oxygen  species
(ROS) and oxidative stress may play an important role [12,
13]. Other study has suggested that oxidative stress may be
involved directly in optic nerve neuropathy due to retinal
ganglion cells (RGC) damage [14]. Furthermore, ROS may
compromise TM integrity favoring IOP increase which is
believed to be the major risk factor of POAG [15].
Our results indicate that the oxidative damage may be
considered as one of ethiopathogenic factors involved in both
POAG development and the more severe phenotypes of this
disease. We found that GSTM1 null genotype, alone, was
associated  with  a  more  than  twofold  risk  among  POAG
patients. When combined with the GSTT1 positive genotype
and the variant genotypes of GSTP1 (dominant model), there
was a risk of 2.4 and 2.7 (OR), respectively. The GSTM1 null
genotype was associated with higher IOP levels (p=0.009),
more severe damage to the optic nerve (p=0.006) and visual
field  (p=0.033).  We  suggest  that  this  genotype  may  be
considered one of the genetic risk factors for the development
of POAG and could be used as a genetic marker for the
Figure 1. Differences of means for the
parameter initial IOP of the right eye for
the combined genotypes of GSTM1 and
GSTT1. The mean of initial IOP to the
right eye was significantly higher in the
POAG patients carrying the GSTM1-/
GSTT1+  genotype  combination
compared to those with the GSTM1+/
GSTT1+ combination. *CI: Confidence
Interval.
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1683disease. The GSTT1 null genotype was more frequent in the
control group than in the case group. Although this increased
prevalence was not statistically significant, but it is suggestive
of protection among the carriers. This hypothesis has been
suggested by Kim et al. [16] and Rebbeck [17] in association
studies involving hepatocellular carcinoma and head and neck
cancer,  degenerative  diseases  where  oxidative  stress  was
shown to play an important role, like POAG. Additionally, it
was shown that workers with GSTT1 null genotype exposed
to polycyclic aromatic hydrocarbons had lower concentration
of  8-oxyguanine,  the  main  biomarker  of  oxidative  DNA
damage, when compared to individuals with GSTT1 positive
genotype [18].
The association of the GSTM1 null genotype with POAG
has been previously described in other studies [15,19] and was
first observed by Izzotti et al. [20]. These authors found a
higher risk of POAG development (OR=15) among GSTM1
null carriers when compared with healthy volunteers. They
also observed a more than threefold increase of 8-hydroxy-2
´-deoxyguanosine (8-OH-dG) levels, an indicator of oxidative
DNA damage in the TM tissue of POAG patients among
GSTM1 null phenotype carriers. GSTM1 non null carriers did
not show an increase of 8-OH-dG levels. The TM tissue was
used by the authors to identify GST genotypes because TM is
believed to be the tissue where primary damage is thought to
occur.  Their  result  is  considered  a  new  perspective  in
understanding POAG physiopathology and in elucidating the
role of oxidative stress in glaucoma [21]. Yildirim et al. [22]
on  analyzing  a  Turkish  population,  also  found  higher
GSTM1 null genotype frequencies in POAG patients when
compared with healthy volunteers. They described 1.6 higher
risk  of  development  of  POAG.  Contrary  to  our  results,
Juronen et al. [6] found that the GSTM1 positive genotype was
associated with higher risk of development of POAG when
compared with control group (OR=1.83) while Jansson et al.
[8] could not demonstrate any significant association between
POAG and GST polymorphisms.
GST  enzymes  protect  cells  against  electrophilic
compounds, endogenous oxidants, and end products formed
as secondary metabolites during oxidative stress. Abu-Mero
et al. [23] had suggested that decrease GST enzyme activity
may contribute to glaucomatous optic neuropathy, although
the  exact  mechanism  still  remains  to  be  elucidated.  It  is
possible that decreased GST enzyme activity might contribute
to  oxidative  damage  directly  at  retinal  ganglion  cells  in
genotype null carriers, or perhaps, any alteration in catalytic
activity of the drug-metabolizing enzymes such as GSTM1
may compromise detoxification in TM thus leading to POAG.
In  fact,  some  studies  have  demonstrated  that  chronic
oxidative stress may compromise the integrity of the TM
[24,25].  Green  et  al.  [25]  demonstrated  that  TM  cells
submitted to long period of exposure to H2O2 in aqueous
humor, had altered defense mechanisms and lowered their cell
numbers in the in vitro studies. Although catalases catalyze
degradation  of  H2O2  at  higher  concentrations,  there  are
evidences that GST protects ocular tissues against damage
when lower concentrations of H2O2 are present [19]. Repeated
oxidative stress events may compromise adherence of TM
Figure 2. Differences of means for the
parameter of optic nerve damage (ONR:
DEF) of the right eye for the combined
genotypes of GSTM1 and GSTP1. The
POAG patients carrying the higher-risk
genotype combination of GSTM1 and
GSTP1  (GSTM1-/GSTP1  variant)
presented  higher  mean  value  of
ONR:DEF than individuals carrying at
least one functional copy of GSTM1.
*CI: Confidence Interval.
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1684cells leading to out flow of the aqueous humor [26]. In POAG
patients, it is plausible to say that chronic oxidative stress
related to aging, an established risk factor for the development
of glaucoma, may be an additional risk factor for progression
to glaucomatous disease.
In  our  study,  the  right  eye  showed  more  relevant
alterations in higher IOP levels, visual fields and optic nerve
defects. These results are in agreement with the observation
of asymmetry between both eyes in glaucomatous disease
observed  in  clinical  practice.  It  also  suggest  that  besides
genetic factors, there are other factors are implicated in this
complex disease [27].
In summary, our study is the first case-control to try to
associate GST genotype and POAG in the American continent
combined with clinical evaluations like IOP, optic nerve, and
visual field defects. The population under study is located in
an area supposedly composed of genetic diversity established
over  500  years,  which  consists  of  European  immigrants
(mainly  Portuguese),  Africans  and  the  Native  American
population (Tupinamba). Moreover, it is the first study to
identify an increased frequency of association of GSTM1 null
genotype  and  GSTP1Ile/Val  or  GSTP1Val/Val  in  patients
with glaucoma and the influence of these polymorphisms with
severity  of  the  disease.  We  would  like  to  note  here,  that
analysis of other enzyme polymorphisms is necessary to be
undertaken to further elucidate the pathophysiology of this
complex disease. It might be possible in the near future to
perform genetic based diagnoses in the early stages of the
disease, thus preventing blindness associated with the disease.
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Appendix 1.
Power analysis of the positive findings reported in present study. To access the data, click or select the words “Appendix 1.”
 This will initiate the download of a compressed (pdf) archive that contains the file.